We are live on !
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
Turnover
60.61%
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
(+14%)
Cap. Flow
+$2.99M
Cap. Flow % of AUM
Cap. Flow %
4.5%
Top 10 Holdings %
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Avg Time Held
Equity + Options
0.5
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$3.53M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$2.94M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$2.18M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$1.54M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$1.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Mills
GIS
|
+$2.52M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$2.31M |
| 3 |
Amgen
AMGN
|
+$2.08M |
| 4 |
Abbott
ABT
|
+$1.72M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.45% |
| 2 | Miscellaneous | 41.8% |
| 3 | Consumer Discretionary | 7.1% |
| 4 | Consumer Staples | 6.25% |
| 5 | Communication Services | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
NBRV
76
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $164K | 0.25% |
80
+20
| +33% | +$46.9K |
2016 Q1
6 quarters
|
|
|
LJPC
77
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $159K | 0.24% |
+4,560
| New | +$147K |
2017 Q3
0 quarters
|
|
78
CALL
Sarepta Therapeutics
SRPT
$2.02B
| $157K | 0.24% |
24,300
+8,000
| +49% | +$320K |
2015 Q4
7 quarters
|
|
79
The Kraft Heinz Company
KHC
$28.3B
| $155K | 0.23% |
+2,000
| New | +$167K |
2017 Q3
0 quarters
|
|
80
PUT
Mondelez International
MDLZ
$81.7B
| $148K | 0.22% |
73,000
+8,000
| +12% | +$340K |
2016 Q2
5 quarters
|
|
81
PUT
Gilead Sciences
GILD
$194B
| $147K | 0.22% |
+100,000
| New | +$7.65M |
2017 Q3
0 quarters
|
|
|
OTIC
82
DELISTED
Otonomy, Inc.
OTIC
| $147K | 0.22% |
45,101
-13,306
| -23% | -$179K |
2016 Q1
6 quarters
|
|
|
ZYNE
83
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $146K | 0.22% |
17,500
+15,000
| +600% | +$159K |
2017 Q2
1 quarter
|
|
84
PUT
DELISTED
bluebird bio
BLUE
| $143K | 0.22% |
+1,004
| New | +$1.4M |
2017 Q3
0 quarters
|
|
85
DELISTED
Foot Locker
FL
| $141K | 0.21% |
+4,000
| New | +$168K |
2017 Q3
0 quarters
|
|
86
PUT
AbbVie
ABBV
$511B
| $135K | 0.2% |
50,000
+40,000
| +400% | +$3.04M |
2016 Q1
6 quarters
|
|
87
CALL
Coca-Cola Europacific Partners
CCEP
$49.8B
| $133K | 0.2% |
33,000
| – | – |
2016 Q2
5 quarters
|
|
88
VanEck Gold Miners ETF
GDX
$26.2B
| $132K | 0.2% |
+5,765
| New | +$133K |
2017 Q3
0 quarters
|
|
89
PUT
Regeneron Pharmaceuticals
REGN
$83.1B
| $125K | 0.19% |
4,500
-8,500
| -65% | -$4.04M |
2015 Q4
7 quarters
|
|
90
DexCom
DXCM
$32.4B
| $122K | 0.18% |
+10,000
| New | +$177K |
2017 Q3
0 quarters
|
|
|
POT
91
DELISTED
Potash Corp Of Saskatchewan
POT
| $121K | 0.18% |
6,300
-33,780
| -84% | -$602K |
2015 Q4
7 quarters
|
|
92
PUT
Nike
NKE
$56.3B
| $116K | 0.17% |
+20,400
| New | +$1.15M |
2017 Q3
0 quarters
|
|
|
FCSC
93
DELISTED
Fibrocell Science Inc.
FCSC
| $116K | 0.17% |
+7,600
| New | +$123K |
2017 Q3
0 quarters
|
|
|
CLVS
94
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
| $112K | 0.17% |
49,600
-15,000
| -23% | -$1.19M |
2017 Q1
2 quarters
|
|
95
CALL
Cal-Maine
CALM
$2.88B
| $105K | 0.16% |
+45,000
| New | +$1.68M |
2017 Q3
0 quarters
|
|
96
PUT
Akebia Therapeutics
AKBA
$171M
| $104K | 0.16% |
+30,000
| New | +$461K |
2017 Q3
0 quarters
|
|
97
CALL
DELISTED
Chimerix, Inc.
CMRX
| $99K | 0.15% |
+150,000
| New | +$738K |
2017 Q3
0 quarters
|
|
|
LOXO
98
CALL
DELISTED
Loxo Oncology, Inc
LOXO
| $97K | 0.15% |
+10,000
| New | +$777K |
2017 Q3
0 quarters
|
|
99
CALL
PTC Therapeutics
PTCT
$5.25B
| $95K | 0.14% |
+53,000
| New | +$1.04M |
2017 Q3
0 quarters
|
|
100
CALL
Acadia Pharmaceuticals
ACAD
$3.52B
| $94K | 0.14% |
10,900
+700
| +7% | +$22.8K |
2016 Q1
6 quarters
|
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2017 Portfolio in Review
As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
FT Options deployed $2.99M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.
- FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
- FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
- FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
- FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
- FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
- FT Options opened 108 new positions and closed 72 in Q3 2017.
- FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.
Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.